THERAPY DOSSIER · th-955b2178234a

Human recombinant endostatin

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL4297747 ↗
ChEMBL max phase: 3 / 4 (development scale, not regulatory approval)
Synonyms: Endostatin; YH 16; YH-16
Note: Not recorded

Clinical trials 9

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01689558 ↗PHASE2/PHASE3unknown

Recombinant Endostatin With Neoadjuvant Chemotherapy and Chemoradiation in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Enrolment: 60 · Results not recorded

NCT03121833 ↗PHASE2completed

Recombinant Human Endostatin (Endostar) Combined With Chemotherapy for Stage IV Soft Tissue Sarcoma

Soft Tissue Sarcoma, Adult, Stage IIB

Enrolment: 52 · Results not recorded

NCT00604435 ↗PHASE2completed

Neoadjuvant Recombinant Human Endostatin, Docetaxel and Epirubicin in Breast Cancer

Breast Cancer

Enrolment: 69 · Results not recorded

NCT05514275 ↗PHASE2recruiting

Radiotherapy With Recombinant Human Endostatin and Capecitabine for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Enrolment: 41 · Results not recorded

NCT01527864 ↗PHASE2unknown

Paclitaxel-Carboplatin With Pegylated Endostatin for Advanced NSCLC

Non Small Cell Lung Cancer

Enrolment: 300 · Results not recorded

NCT03614065 ↗PHASE2unknown

Endostar Combined With Radiotherapy in Brain Metastasis of NSCLC

Non-small Cell Lung Cancer

Enrolment: 50 · Results not recorded

NCT07154108 ↗PHASE1not yet recruiting

Recombinant Human Endostatin Adenovirus With Immune Checkpoint Inhibitors in Head and Neck / Esophageal Cancer

Esophageal Cancer · Head and Neck Cancer

Enrolment: 40 · Results not recorded

NCT01301443 ↗PHASE1completed

Subretinal RetinoStat (Endostatin/Angiostatin Lentiviral Vector) in Neovascular AMD

Age Related Macular Degeneration

Enrolment: 21 · Results not recorded

NCT01260025 ↗PHASE1completed

PEGylated Recombinant Human Endostatin (M2ES) in Advanced Solid Tumor

Tolerability · Pharmacokinetics · Endostatin

Enrolment: 20 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31816619 ↗2019Mixed findings

The Construction of a Radiation-Induced Brain Injury Model and Preliminary Study on the Effect of Human Recombinant Endostatin in Treating Radiation-Induced Brain Injury.

RatRadiationSprague-Dawleymalen = 3 rats per group at each time point; total and survival coh…Intraperitoneal injection2 mL/kg body weight; mass concentration not statedBeginning after irradiation on day 1

Model: Whole brain irradiation with a 6 MV electron beam, single fractionated dose of 20 Gy at 2 Gy/min, source to skin distance 100 cm

Endostatin appeared to aggravate cerebral oedema and weight loss in the acute stage and reduced survival by day 56, while lowering oedema progression in the early delayed stage, so the overall effect was mixed and leaned unfavourable.

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…